Past medical history will be gathered to assess for possible contraindications. Other causes of headache will be ruled out with appropriate imaging and laboratory studies. Patients with headache possibly attributed to other cause will be excluded. Patients without prior migraine, with sudden onset pain (i.e. thunderclap headache), with focal neurologic deficits (other than visual field changes), or other evidence of underlying neurologic pathology will be excluded. Head pain must be refractory to current standard or care treatment for status migrainosus.

If pain responds to treatment, as defined by a 50% reduction in pain on a 10 point visual analog pain scale, the patient will be excluded. A CT of high throughput screening assay the head at presentation ABT 199 will be obtained to assess for intracranial pathology that would warrant exclusion. Subjects should be screened to exclude significant risks for undergoing an extended course of

HBO2T including ejection fraction of <35%, an ABG, and radiographic evidence of pulmonary blebs or bullae. Prior to treatment the patient will report subjective level of pain based on the visual analog pain scale, due to prior studies showing this measure was the best indicator of relief. If no exclusion exists, the patient will be randomized to HBO2T or sham treatment. Only the technician administrating the therapy will be aware of which treatment the patient receives. HBO2T will consist of 100% oxygen at 2.4 ATA for 90 min for one treatment. Post-treatment the patient will again be assessed for pain based on visual analog pain scale. A positive response will be defined as a 50% pain reduction using a 10 point visual analog pain scale which will serve as the primary outcome of the study. Patients will also be assessed, directly or by phone, at 24 and 48 h for duration of the effect of the therapy and frequency of recurrence of migraine pain. This study was supported in part by a Bleser Endowed Chair of Neurology to Harry T. Whelan, MD, Chad Ergoloid Baumann

Neurology Research Endowment to Harry T. Whelan, MD, US Department of Health and Human Services grant, NIH 1R21AT003002-01A1 to Harry T. Whelan, MD. According to order. None declared. The authors wish to gratefully acknowledge the administrative support of Debbie Dye, throughout this project, and manuscript preparation. “
“Neisseria meningitidis (dwoinka zapalenia opon mózgowo-rdzeniowych, meningokok) należy do najczęstszych bakteryjnych czynników etiologicznych zapalenia opon mózgowo-rdzeniowych (ZOMR) i sepsy na świecie, obarczonych dużym ryzykiem powikłań i wysoką śmiertelnością. Przebieg zakażenia może być niezwykle dramatyczny i prowadzić w ciągu kilku godzin do zgonu chorego. Największe ryzyko zachorowań dotyczy małych dzieci, zwłaszcza poniżej pierwszego roku życia. Szczepy N.